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Huntington’s disease is caused by a CAG repeat expansion in exon 1 of the HTT gene. We
have previously shown that exon 1 HTT does not always splice to exon 2 producing a small
transcript (HTTexon1) that encodes the highly pathogenic exon 1 HTT protein. The
mechanisms by which this incomplete splicing occurs are unknown. Here, we have generated
a minigene system that recapitulates the CAG repeat-length dependence of HTTexon1 pro-
duction, and has allowed us to deﬁne the regions of intron 1 necessary for incomplete splicing.
We show that manipulation of the expression levels of the splicing factor SRSF6, predicted to
bind CAG repeats, modulates this aberrant splicing event and also demonstrate that RNA
polymerase II transcription speed regulates the levels of HTTexon1 production. Understanding
the mechanisms by which this pathogenic exon 1 HTT is generated may provide the basis for
the development of strategies to prevent its production.
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Huntington’s disease (HD) is a devastating hereditaryneurodegenerative disorder that manifests with motoric,cognitive and psychiatric symptoms1. The mutation is a
CAG repeat expansion in exon 1 of the huntingtin gene (HTT)2,
which translates to a polyglutamine (polyQ) track in the hun-
tingtin protein (HTT). In addition to the three full length iso-
forms3–5, other isoforms consisting of a combination of the
inclusion of cryptic exons6,7, retention of parts of introns and
alternative splice site usages7–9 have been identiﬁed. However,
these isoforms are subject to nonsense mediated RNA decay and
will have no functional consequences. In contrast, the highly
pathogenic exon 1 HTT protein with an expanded polyQ track is
sufﬁcient to model numerous HD related phenotypes in many
species10–12. We have shown that exon 1 HTT is produced by a
block in splicing of HTT exon 1 to exon 2 that generates a small
transcript, comprising the 5′ UTR, exon 1 and terminating at
cryptic polyA sites in intron 1 (HTTexon1)13. This transcript is
produced in a CAG repeat length-dependent manner in all
knock-in mouse models of HD and in HD patient tissue14. We
have proposed that this block in splicing is at least partly medi-
ated by abnormal binding of the splicing factor SRSF6 to the CAG
repeat. This in turn could interfere with the formation of the
spliceosome at the 5′ splice site and/or expose cryptic polyA sites
in intron 113,15.
The production of HTTexon1 by incomplete splicing is CAG
repeat-length dependent13,14. Therefore, somatic instability of
CAG repeats, which can lead to vastly increased CAG repeat
lengths, would in turn lead to much higher levels of HTTexon1
and of the pathogenic exon 1 HTT protein14. Recent genome-
wide association studies uncovered several DNA ﬁdelity main-
tenance factors that inﬂuence HD onset and/or progression16,17
and are also known to modulate CAG repeat stability18–20. This is
also inﬂuenced by transcription elongation by RNA polymerase II
(PolII), in particular certain chromatin marks and R-loops, stable
DNA:RNA hybrid structures, correlate with an increase in repeat
instability21,22. R-loops also play an important role in the reg-
ulation of alternative splicing23 and the termination of tran-
scription24. Transcription and splicing are tightly linked and
inﬂuence each other25. The ‘window of opportunity’ model of
splicing states that a certain kinetic window of transcription will
allow splicing with a deﬁned pattern. In other words, fast elon-
gation speeds usually favor exclusion and slow elongation speeds
inclusion of exons with weaker 5′ and/or 3′ splicing signals25.
Additionally, polyA site selection and protein binding to the
nascent RNA, inﬂuenced by differential folding of the RNA due
to different PolII speeds, might be tied to transcriptional speeds25.
Fitting with this hypothesis, and further strengthening the link
between transcription and splicing, PolII pauses at the 3′ and 5′
splice sites, which deﬁne the exons26,27 and there is a polyA site
dependent checkpoint of transcription termination28.
To facilitate the analysis of mechanisms that contribute to the
incomplete splicing of HTT, we generated a human cell-based
minigene system. In this model, we observe the same CAG repeat
length-dependent splicing of Htt minigenes that we discovered in
mouse models of HD and in HD patients13,14. Using this system,
we can deﬁne the minimal sequences necessary for canonical
splicing of Htt, as well as the intronic regions that are required to
induce incomplete splicing. Furthermore, we show that modula-
tion of the splicing factor SRSF6 regulates exon 1 to exon 2 spli-
cing in the context of an expanded CAG repeat, highlighting the
important function of SRSF6 in this process. Given the tight link
between transcription and splicing, we analyzed PolII transcrip-
tion across the minigenes. We ﬁnd clear differences in PolII
occupancy along the minigenes that contain control as compared
to elongated CAG repeats. Corroborating these ﬁndings, treat-
ment with drugs that affect transcription and introducing ‘road
blocks’ in the gene by CRISPR/dCAS result in differences in the
levels of HTTexon1 production.
Results
Generation of a cell model of incomplete splicing of Htt. To
dissect the mechanism underlying incomplete splicing in HD, we
constructed a variety of mouse Htt minigenes. We chose to
express these in a human cell line (human embryonic kidney
ﬁbroblasts—HEK293) (Fig. 1a) for a number of reasons. First, the
mouse Htt sequences could be distinguished from endogenous
human HTT. Second, one of the cryptic polyA sites utilized in the
human gene is located 7.3 kb into intron 1, limiting the feasibility
of cloning multiple comparative constructs, because the human
HTT intron 1 sequences are extremely GC rich and difﬁcult to
work with14. Finally, the similarity of the 5′ region of the mouse
and human HTT genes, and the high level of conservation
between the human and mouse splicing machinery suggested that
this would be a feasible approach
All constructs contained the mouse Htt promoter, 5′ UTR,
exon 1, the ﬁrst (5′) 917 bp of intron 1, the last (3′) 338 bp of
intron 1, exon 2 fused to a FLAG-tag and mouse Htt 3′ UTR
sequences including the ﬁrst mouse polyA site (Fig. 1a). We
hypothesized that these domains would constitute the core
sequences required for the splicing of the minigenes (Fig. 1b,
short). To determine, which additional intronic sequences would
be required to recapitulate incomplete splicing, we inserted
additional segments of intron 1 downstream to the core 5′
intronic sequences (Fig. 1b). These included the sequences that
were found by RNAseq13 to be part of HTTexon1 (Fig. 1b,
medium), or, in addition, the following 1.3 kb, which included
GT/GA repeats and a predicted terminator like hairpin, both
possibly acting as transcriptional modulators (Fig. 1b, long). As a
control, for a situation in which no exon 1 to exon 2 splicing had
occurred, we created minigenes that consisted of the mouse Htt
promoter, 5′ UTR, exon 1 and the ﬁrst (5′) 917 bp of intron 1
only (Fig. 1b, ex1 only). Constructs were generated with a range
of CAG repeat lengths including: (CAG)7, (CAG)23, (CAG)32,
(CAG)41, (CAG)54 and (CAG)103.
Constructs were transfected into HEK293 cells using the ‘Flp-
In’ system to create an isogenic series of stable lines. The
generation of HTTexon1 involves the usage of cryptic polyA sites
in intron 1, of which several are predicted for mouse Htt
(Supplementary Fig. 1A). We had previously identiﬁed the site at
677 bp into intron 1 as being used in the HdhQ150 mouse model.
This site is present in all of the minigene constructs. A second site
was predicted by the RNAseq reads from the HdhQ150 mice, that
extended up to approximately 1.2 kb into intron 113 and we can
now conﬁrm that this is located 1145 bp into intron 1
(Supplementary Fig. 1B). We applied 3′RACE to the minigene
lines and found that only the ﬁrst cryptic polyA site was used
(Fig. 1c and Supplementary Fig. 1C), to produce a polyadenylated
transcript (HTTexon1) in the long intron lines, but not in the
short and medium intron lines (Fig. 1c).
In the control situation with (CAG)7, splicing should produce
an exon 1-exon 2-FLAG fusion protein. With an expanded CAG
repeat, the Htt minigene should be at least partially incompletely
spliced and an exon 1 HTT protein should also be produced
(Fig. 1d). Consistent with this hypothesis, we could detect the
properly spliced exon 1-exon 2-FLAG fusion proteins and an
exon 1 HTT protein fragment in the long intron minigene lines
with an expanded CAG repeat consistent with the 3′RACE data
(Fig. 1e and Supplementary Fig. 2, compare Fig. 1c).
We next used real-time quantitative PCR (qPCR) to identify
the minigene transcripts that were present in the cell lines. As
outlined above, canonical splicing with (CAG)7, should lead to
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06281-3
2 NATURE COMMUNICATIONS |  (2018) 9:3955 | DOI: 10.1038/s41467-018-06281-3 | www.nature.com/naturecommunications
the generation of a properly spliced exon 1-exon 2 transcript
(Fig. 2a). For longer CAG repeats (>(CAG)40) a subset of the
splicing reactions should be blocked and HTTexon1 should be
generated (Fig. 2a, right panel). HTTexon1 contains sequences of
the 5′ part of intron 1 (light blue in Fig. 2a), which are normally
spliced out and degraded. We used the retention of these
sequences as a surrogate measure for incomplete splicing (Fig. 2b,
intron 1 assay). Canonical splicing was measured with a qPCR
assay, in which the forward primer binds in exon 1 and the
reverse primer binds in exon 2 of the minigene constructs
(Fig. 2b, spliced exon 1-exon 2 assay).
We then examined the extent to which splicing had occurred in
the minigene transcripts. To exclude the potential inﬂuence of
different levels of transcription when comparing minigene
derived exonic or intronic transcripts between constructs, they
were ﬁrst normalized to their respective 5′ UTR levels, unless
otherwise noted, as these should not be inﬂuenced by any
downstream events (see also Fig. 2b, 5′ UTR assay). The level of
the exon 1 to exon 2 fusion transcript was measured to determine
the extent to which complete splicing had occurred. In all lines,
we could detect properly spliced minigene transcripts for all CAG
repeat lengths (Figs. 2d, f, h and j). The short intron lines showed
the highest, and the long intron lines the lowest, expression levels
over housekeeping (HK) genes (Fig. 2j). Previous publications
have shown a reduction in full-length mutant HTT levels that
occurs in mouse models of HD and in patient tissue13,14. We only
observed a decrease in spliced transcript levels with increasing
CAG repeat length in the long intron lines (Fig. 2h).
Incomplete splicing results in the retention of 5′ intronic
sequences in the HTTexon1 transcript, and we used these levels as
a measure for incomplete splicing (Fig. 2a, b). Interestingly, the
short intron lines, which gave rise to properly spliced minigene
transcripts (Fig. 2d) and thus contain all sequences necessary for
canonical splicing, showed a minor CAG repeat length-dependent
retention of intron 1 (Fig. 2e). Also the addition of subsequent
intronic sequences (medium lines) did not result in a CAG repeat
dependent increase in incomplete splicing of the minigene
constructs (Fig. 2g). In contrast, the long intron minigene lines
exhibited readily detectable levels of intronic sequences (Fig. 2i).
Consistent with mouse data, incomplete splicing increased with
increasing CAG repeat length, and at longer repeats, ≥(CAG)54,
reached very high levels, comparable to the expression levels of
the exon 1 only construct (Fig. 2i, compare long intron to exon 1
only). Furthermore, intron 1 levels (Fig. 2k) were largely inversely
correlated to spliced levels (Fig. 2j), indicating that the
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Fig. 1 Development of a cell based system that recapitulates incomplete splicing of Htt. a Schematic showing the elements of the Htt minigenes. b Three
minigene constructs differed only in the length of 5′ intron sequences (short: 917 bp; medium: 1848 bp; long: 3160 bp). One construct contained only the
coding sequence for exon 1 HTT and the ﬁrst 916 bp of intron 1 (ex1 only). c 3′RACE analysis showed that the cryptic polyA site at 677 bp into intron 1
(arrowhead) was only used in the long minigene lines with a threshold of about 40 CAGs. d Proteins that will be expressed from these constructs: Splicing
will generate an exon 1-exon 2-FLAG fusion protein (control and expanded CAG). In the case of an expanded CAG, an exon 1 HTT protein will also be
generated due to incomplete splicing of exon 1 to exon 2. e Overlay image of spliced (FLAG) and exon 1 HTT (S830) containing fragments. HTT fragments
were immunoprecipitated (IP) with 3B5H10 coupled magnetic beads and immunoprobed (IB) with antibodies as indicated (please see Supplementary Fig. 2
for complete protein analysis). FLAG-tag detects the properly spliced exon 1–exon 2 fragment (2) (see also Fig. 1d). The S830 antibody recognized Q50
and Q100 containing spliced (2), as well as incompletely spliced fragments (1: Q50, 3: Q100). Q7 containing fragments were not detected because they are
not efﬁciently immunoprecipitated with the anti-polyQ antibody 3B5H10. PL parent line; M marker
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06281-3 ARTICLE




































































7 23 32 37 41 54 103
CAG repeats
Spliced exon 1- exon 2




























































7 23 32 37 41 54 103
CAG repeats
* * *
Spliced exon 1- exon 2
































































































Endogenous HTT (exon 66/67)
















































































































Spliced exon 1- exon 2
5'UTR
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06281-3
4 NATURE COMMUNICATIONS |  (2018) 9:3955 | DOI: 10.1038/s41467-018-06281-3 | www.nature.com/naturecommunications
endonucleolytically cleaved pre-mRNA and not through addi-
tional transcription. To determine whether expression of the
minigenes might interfere with the expression of endogenous full-
length human HTT in trans, we measured the levels of exon 66/67
containing HTT transcripts by qPCR (Fig. 2c). There were no
consistent CAG repeat length-dependent, or construct dependent,
differences in endogenous HTT levels.
Since CAG repeats are unstable, we analyzed the CAG repeat
lengths in our cell lines during continuous growth over 15
passages (approximately 50 days). We only detected instability in
the (CAG)100 lines, which was independent of the occurrence of
incomplete splicing (Supplementary Fig. 3A and 3B, long vs.
medium intron 1 lines). The levels of incompletely spliced
minigenes remained unchanged (Supplementary Fig. 3C), while
endogenous HTT levels declined (Supplementary Fig. 3D).
In summary, we have deﬁned the essential regions of the 5′ Htt
gene necessary for canonical splicing, as well as for the
incomplete splicing of Htt. Furthermore, our cell model showed
CAG repeat length-dependent incomplete splicing and used the
same cryptic polyA site as in mouse models of HD.
SRSF6 levels modulate the amount of HTTexon1 production.
We have previously shown that the general splicing factor SRSF6
binds to the 5′ end of Htt transcripts, consistent with the pre-
diction that it recognizes a CAG repeat13. We propose that SRSF6
at this ectopic location could interfere with spliceosome assembly
at the 5′ splice site of intron 1 and/or inhibit the protection of
cryptic polyA sites in intron 1 by U1 snRNP (U1 RNA containing
small nuclear ribonucleoproteins). We increased (Fig. 3a–e) and
reduced (Fig. 3f–i) the levels of SRSF6 to test whether this could
modulate the amount of incompletely spliced Htt. Since we
observed pronounced levels of incompletely spliced HTTexon1 in
cell lines with a highly expanded CAG repeat, (CAG)100 in
comparison to (CAG)7, we focused on these two CAG repeat
lengths, in the long intron 1 lines, for all further experiments.
Overexpression of mouse Srsf6 or human SRSF6 led to highly
increased transcript (Fig. 3a, b) and SRSF6 protein levels (Fig. 3c)
independent of the CAG repeat length. Although there was no
detectable reduction in the levels of the spliced minigenes when
either mouse Srsf6 or human SRSF6 were overexpressed, (Fig. 3d),
the amount of incomplete splicing in the (CAG)100 line was
increased with overexpression of mouse Srsf6 and even more so
for human SRSF6 (Fig. 3e). This discrepancy may be because
mouse SRSF6 does not fully integrate into the human spliceo-
some, due to a 5 amino acid difference at the C-terminus (97%
overall amino acid homology). siRNA mediated knock-down of
SRSF6 led to signiﬁcantly decreased transcript (Fig. 3f) and pro-
tein (Fig. 3g) levels for both CAG repeat lengths. Unexpectedly,
we observed that the basal SRSF6 transcript, but not SRSF6
protein levels were lower in the CAG100 compared to the (CAG)7
lines (Figs. 3f, g, scramble). We did not detect any difference in
the levels of spliced minigenes when SRSF6 was knocked-down
(Fig. 3h). In contrast, the reduction in SRSF6 levels resulted in
signiﬁcantly lower levels of incomplete splicing in the CAG100
line (Fig. 3i).
Taken together, we could show that, consistent with our
aforementioned hypothesis, higher levels of SRSF6 increased the
levels of incomplete splicing, and lower levels of SRSF6 led to
signiﬁcantly lower levels of HTTexon1 generation.
In order to determine whether the SRSF6 modulatory effects
on Htt splicing could be recapitulated with other splicing factors,
we overexpressed SRSF1, SRSF2, or SRSF3 in the long intron
minigene lines (Supplementary Fig. 4). In contrast to the
stimulatory effect on incomplete splicing when SRSF6 was
overexpressed (Fig. 3), the overexpression of each of these three
SR proteins led to a decrease in incompletely spliced Htt
minigenes, while normal splicing was not changed (Supplemen-
tary Fig. 4). The overexpression of these splicing factors most
likely inﬂuences the splicing of the Htt minigenes through
secondary effects, based on changes in the transcriptome.
To determine whether the splicing machinery was dysregulated
in general, we used the KEGG pathway genes for spliceosome
(mouse: mmu03040; human: hsa03040) and analyzed their
expression levels in several tissues of a mouse model of HD at
6 months of age, and in human post mortem brain tissue
(Supplementary Fig. 5). There was no general dysregulation of the
splicing machinery, and no consistent changes between tissues.
Given that we have previously shown that incomplete splicing of
HTT occurs in these HD mice at 2 months of age13 and in this
post mortem brain region14, this incomplete splicing is likely to
be caused by a transcript speciﬁc mechanism, rather than to
general dysregulation of the splicing machinery.
The position of the CAG repeat inﬂuences splicing of Htt. We
next tested whether the presence of a CAG repeat would be
sufﬁcient to induce splicing changes, irrespective of its’ spatial or
genetic context. The binding of SRSF6 to the CAG repeat could
interfere with spliceosome formation at the 5′ splice site (end of
exon 1). Therefore, moving the CAG repeat away from the 5′
splice site could potentially reduce this interference effect. To test
this, we created minigenes, in which a (CAG)23 or (CAG)100
repeat ﬂanked by 19 bp upstream and 18 bp downstream
sequences was placed either in the 5′ UTR (BamHI site) or in
intron 1 (KpnI site) of the CAG7 containing long intron backbone
(Fig. 4a). The 5′ UTR integrated lines retained a certain level of
incompletely spliced HTTexon1, albeit to a lower extent than the
normal minigenes, and a concomitant decrease in the spliced
exon 1–exon 2 transcript (Fig. 4b). In contrast, integration of the
CAG repeats in intron 1 did not induce incomplete splicing
(Fig. 4c). However, we could not detect any spliced product in
these lines (Fig. 4c). We hypothesized that the integration into the
5′ region of intron 1 might have interfered with the assembly of
Fig. 2 Incomplete splicing of Htt in the minigene lines. a Schematic showing possible transcripts arising from the different minigene constructs. For a
control CAG repeat (CAG)7 only properly spliced exon 1–exon 2 transcripts are expected. In the case of an elongated CAG repeat (>(CAG)40), in addition
to the canonically spliced transcripts, HTTexon1 is potentially generated. b Position of the qPCR assays. HTTexon1 generation is measured by the amount of
retained intron 1 (intron 1 assay). c–k Transcript analysis in minigene expressing cell lines. Data are mean ± s.e.m.; n≥ 3 independent cell lines/CAG-
length/intron-length; two-way ANOVA with Bonferroni post hoc. Comparison of CAG-length to (CAG)7 for each of the respective construct: *p < 0.05, **p
< 0.01, ***p < 0.001. Comparison of long vs. medium intron constructs for a given CAG-length: #p < 0.05, ##p < 0.01, ###p < 0.001. Comparison of long vs.
short intron constructs for a given CAG-length: ††p < 0.01, †††p < 0.001. Comparison of medium vs. short intron constructs for a given CAG-length:
‡p < 0.05. c Endogenous HTT levels (parent line) were not changed due to the expression of any of the minigene constructs with any CAG-length.
d, f, h Canonically spliced exon 1–exon 2 transcripts. A change with longer CAG lengths was only visible in the long intron lines (h). e, g, i Incomplete
splicing of the minigene constructs measured by retention of 5′ intron 1 sequences. Signiﬁcantly CAG repeat length dependent generation of HTTexon1 was
only detected in the long intron lines starting at a threshold of about 40 CAGs (i). j, k Spliced exon 1–exon 2 minigene transcripts (j) were largely inversely
correlated with incompletely spliced minigenes (k)
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the spliceosome at the 5′ splice site or with site selection, which
would lead to larger spliced transcripts that might be difﬁcult to
detect by qPCR. To test this, we ampliﬁed exon 1 to exon
2 spanning sequences with the same primers as in the exon
1–exon 2 spliced qPCR assay (Fig. 4d). We detected a single band
for the (CAG)23 line in which the CAG repeat had been inte-
grated into the 5′UTR (Fig. 4d, BamHI, 1), representing a
properly spliced exon 1–exon 2 mRNA. In the lines in which the
CAG repeats had been integrated into intron 1, we could only
detect this product at very low levels in the (CAG)23 line, together
with additional multiple longer PCR products (Fig. 4d, KpnI
CAG23, 2). There was no properly spliced product detectable in
the KpnI (CAG)100 lines (Fig. 4d), conﬁrming the qPCR result
(Fig. 4c). We sequenced some of the additional larger transcripts
(Fig. 4d, 3-7). Comparison of all 5′ splice sites with the consensus
sequence (Fig. 4e) conﬁrmed that the 5′ splice site of Htt in the
smallest product corresponded to the exon 1–exon 2 spliced
transcript (Figs. 4d–f, 1 and 2). We uncovered several novel 5′
splice sites that had become activated upon integration of the
CAG repeat into intron 1 (Fig. 4f).
To analyze if a CAG repeat alone would be sufﬁcient to
interfere with splicing in another genetic context, we introduced a
(CAG)23 or (CAG)100 repeat into unrelated SDHA or SPP1
minigenes (Supplementary Fig. 6) but were unable to detect
changes in their splicing pattern.
In summary, a CAG repeat alone is not sufﬁcient to alter
splicing, but needs to be in a precise spatial position to the 5′
splice site.
PolII elongation rate modulates the amount of HTTexon1.
Transcriptional speed, i.e., elongation rates of PolII, and splicing
are tightly intertwined25. Therefore, we set out to analyze whether
transcriptional speeds varied along the minigenes with different
CAG repeat lengths and could be contributing to the level of
incomplete splicing. We used an antibody against the C-terminal
domain (CTD) of PolII, which recognizes phosphorylated serine
2 in the YSPTSPS CTD repeat and is associated with actively
elongating PolII, to immunoprecipitate PolII/chromatin com-
plexes (ChIP). We immunoprecipitated higher levels of PolII
associated minigene sequences from all along the constructs in
the (CAG)100 versus the (CAG)7 lines (Fig. 5a). This difference
was statistically signiﬁcant for sequences immediately after pro-
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Fig. 3 SRSF6 levels modulate incomplete splicing of Htt. a–e Overexpression of SRSF6 increases the amount of incomplete splicing. Mouse Srsf6 (a) and
human SRSF6 (b), respectively, were over-expressed to the same extent in the CAG7 and CAG100 cell lines. c Western blot data conﬁrmed the over-
expression of mouse and human SRSF6 for both CAG repeat lengths. -=mock; m=mouse SRSF6; h= human SRSF6. Uncropped blots can be found in
Supplementary Fig. 8A. d Spliced exon 1–exon 2 transcripts were not signiﬁcantly changed due to the overexpression of mouse or human SRSF6. e Intron 1
containing transcripts were increased to statistically signiﬁcantly levels when human SRSF6 was over-expressed. Individual data points and the mean ± s.e.
m. are shown. n= 8 independent experiments/CAG-length; two-way ANOVA with Tukey post hoc. Effect of SRSF6 overexpression for a given CAG-length:
###p < 0.001. Effects due to CAG-length for a given treatment: ***p < 0.001. f–i Knock-down of SRSF6 by siRNA treatment (s12740, ThermoFisher)
decreased the amount of incomplete splicing. SRSF6 levels were decreased by siRNA treatment on transcript (f) and protein (g) levels for both CAG repeat
lengths. scr= scramble; si= siRNA treatment. Uncropped blots can be found in Supplementary Fig. 8B. h Spliced exon 1–exon 2 transcripts were not
changed due to the knock-down of SRSF6. i There was a statistically signiﬁcant reduction in the amount of incompletely spliced minigene in the CAG100
line. Individual data points and the mean ± s.e.m. are shown. n= 3–6 independent experiments/CAG-length; two-way ANOVA with Tukey post-hoc.
Treatment for a given CAG-length: *p < 0.05, **p < 0.01, ***p < 0.001. Treatment x CAG-length ###p < 0.001
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sequences (at about 3 kb from the exon 1/intron 1 junction).
Transcript levels of 5′ UTR containing minigene sequences were
only slightly higher in the CAG100 compared to the CAG7 lines
(Fig. 5b, about 1.2-fold). In contrast the PolII co-precipitated 5′
UTR fragments were about 1.7-fold higher (Fig. 5a, p= 0.016). If
we infer rate of transcription from PolII occupancy, for both
CAG repeat lengths, our data suggest that PolII holoenzymes slow
down after transcribing through the repeat and speed up again
towards the end of intron 1 (Fig. 5a). We also observed a sig-
niﬁcantly higher occupancy of PolII after the GT/GA repeats and
the predicted terminator like hairpin in the (CAG)100 line
(Fig. 5a, 2.7–3.1 kb), indicating a slower transcriptional speed in
this region.
We next determined the effects of speciﬁc drugs on incomplete
splicing. We used 5,6-dichlorobenzimidazole 1-β-D-ribofurano-
side (DRB, Fig. 5c–f), (S)-(+)-camptothecin (CAM, Supplemen-
tary Fig. 7A), actinomycin D (ActD, Supplementary Fig. 7B) and
1-hydroxypyridine-2-thione zinc salt (zinc, Supplementary
Fig. 7C) in commonly used concentrations. These compounds,
amongst other possible routes of action, inhibit PolII elongation
by inhibiting entry into elongation mode (DRB) or by blocking
productive elongation (ActD)29. We used CAM treatment as a
control to induce apoptosis30. Zn2+ cations induce hyperpho-
sphorylation of SRSF6 and modulate its′ activity31. In our cell
lines, both ActD and zinc resulted in a signiﬁcant reduction of 5′
UTR containing sequences, comparable to the apoptosis inducing
CAM treatment (Supplementary Fig. 7). Therefore, we had no
conﬁdence in interpreting these results. In contrast, 5′ UTR levels
were relatively unaffected by treatment with lower concentrations
of DRB (10 µM, Fig. 5c–f). Interestingly, DRB treatment increased
the amount of correctly spliced exon 1-exon 2 containing
sequences (Fig. 5d), which was mirrored by a reduction in the
levels of the incompletely spliced product (Fig. 5e, f), suggesting a
shift towards canonical splicing.
To further strengthen our hypothesis, that incomplete splicing
is inﬂuenced by PolII transcriptional speed, we introduced ‘road
blocks’ into our minigenes using CRISPR/Cas932. We used four
different guide RNAs (gRNA) to tether a nuclease deﬁcient Cas9
enzyme (dCas9) to the respective target sequences in the
minigenes (Fig. 6a). The binding of CRISPR/Cas to DNA is
non-covalent and transient. Rather than completely blocking
transcription, we hypothesized that these tethered CRISPR/Cas
complexes would hinder PolII transcription and increase the level
of incomplete splicing observed in the (CAG)100 lines (Fig. 5a). As
a proof of principle, we tethered the complexes to the 5′ UTR
(gRNA I, Fig. 6b), which should decrease the level of overall
transcription, because PolII promoter escape/elongation is
hindered at a very early stage. Indeed, we observed a reduction
in minigene transcript levels for the CAG100, but not the (CAG)7
line (Fig. 6b, left panel 5′UTR and intron 1), possibly because
PolII is already affected in the (CAG)100 lines (Fig. 5a). The
splicing pattern of the minigene transcripts was unaffected for
both CAG repeat lengths (Fig. 6b, right panel, transcript levels
were normalized to 5′ UTR levels). To modulate transcription
further down the minigenes, we tethered the complexes with
gRNAs II and III, respectively, but neither changed overall
transcription, nor splicing patterns (Fig. 6c, d). On the other
hand, the gRNA IV ‘road block’ targeted the region where we had
observed statistically signiﬁcant differences in the PolII occu-
pancy between the (CAG)100 and (CAG)7 lines (Fig. 5a), and this
led to statistically signiﬁcant higher levels of incompletely spliced
product (Fig. 6e).
In summary, our data indicate that slower PolII transcription































































































–3 –2 –1 1 2 3 4 5 6
Exon Intron
Canonical 5′ splice site of exon 1/intron 1
ACC|GUGAGUfound in
















Additional novel 5′ splice sites
GAA|GUGCGG found in (392 bp)















Fig. 4 The spatial relation of the CAG repeats to the 5′ splice site inﬂuences incomplete splicing of Htt. a Schematic showing the integration sites for the
CAG repeat in the (CAG)7 long minigene backbone. Transcript analysis of BamHI (b) and KpnI (c) integrated (CAG)23 and (CAG)100 repeats. Individual
data points and the mean ± s.e.m. are shown. n≥ 4 independent cell lines/integration site, one-way ANOVA with Bonferroni post hoc. CAG-length: *p <
0.05, ***p < 0.001. d RT-PCR with the same primers as used in the exon 1–exon 2-spliced qPCR assay (see Supplementary Table 2). In addition to the
canonically spliced product (1), the integration of a CAG repeat at the KpnI site led to the appearance of multiple RT-PCR products (2-7). e The consensus
5′ splice site sequence from -3 to+ 6 bp. f Novel 5′ splice sites that were utilized when the CAG repeat was inserted into the KpnI site. In bands 3 and 6:
the 3′ KpnI site, used to integrate the CAG repeats, functions as a 5′ splice site. In bands 4, 5 and 7: sequences further downstream of the integrated CAGs
in intron 1, resembling the consensus 5′ splice site became utilized
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transcript. The slower transcription could provide a kinetic
window for polyadenylation factors to recognize and act on the
cryptic polyA sites in Htt intron 1.
Discussion
We have developed a minigene system that recapitulates the
incomplete splicing of HTT, and has allowed us to deﬁne the
sequences necessary for this process. As in the case of HD mouse
models and HD patient tissue, the levels of incomplete splicing
increased with increasing CAG repeat length, and we showed that
the spatial relation of the CAG repeat to the 5′ splice site deter-
mines the amount of incomplete splicing that occurs. Consistent
with our hypothesis, the degree of incomplete splicing could be
modulated by increasing or decreasing the levels of the splicing
factor SRSF6. Finally, we demonstrated that the length of the
CAG repeat governs the rate at which transcription occurs along
the minigene. Targeting PolII with drugs and introducing
obstacles along the gene inﬂuenced PolII elongation speed and,
through this, modulated the level of incomplete splicing.
We generated stably integrated minigene lines, based on the
mouse Htt sequence, and analyzed them in a human cell-
background. The minigenes contained intronic canonical splicing
elements and differed only in the length of the 5′ region of intron
1 (Fig. 1b). We could show that the inclusion of both cryptic
polyA sites, and potential transcription attenuators (long intron
construct), had the effect that the majority of the minigenes were
incompletely spliced, irrespective of the length of the CAG repeat
(Fig. 2). The level of incomplete splicing increased with a
(CAG)100 repeat, to the extent that the level of intron 1 sequences
was equivalent to that in the exon 1–intron 1 only constructs
(Fig. 2k), in which no splicing could take place.
The general splicing factor SRSF6 binds to transcripts with an
elongated CAG repeat13. Here, we have shown that modulation of
its levels (Fig. 3) inﬂuences the extent of incomplete splicing.
Overexpression greatly increased the incomplete splicing of
minigenes (Fig. 3e), while knock-down resulted in reduced levels
of HTTexon1 (Fig. 3i). Could the sequestration of SRSF6 to the
CAG repeats lead to splicing changes other than those of Htt
itself? It is unlikely that this contributes to the tremendous
amount of transcriptional dysregulation that develops with dis-
ease progression in HD. Incomplete splicing of Htt occurs at ages
before the onset of transcriptional dysregulation in HD mouse
models, and even at later ages there seem to be no general
changes in the splicing machinery (Supplementary Fig. 5).
If SRSF6 binds to expanded CAG repeats, and results in
aberrant splicing in HD, might this also be true for the other
CAG-repeat diseases? To date, splicing alterations have only
been identiﬁed for spinocerebellar ataxia type 3 (SCA3) in the
ataxin 3 (ATXN3) gene. In SCA3 a 3′ truncated transcript has
been found in YAC mice harboring the full length human
ATXN3 gene and in patient samples33. Analysis of a knock-in
mouse model of SCA3 suggested that the mechanism for the
generation of this transcript might involve incomplete spli-
cing34. However, this SCA3 mouse model was later found to
harbor a duplication of the CAG repeat and, when corrected,
this mouse no longer exhibited the splicing changes35,36. The
authors proposed that the thymidine kinase (TK) gene, which
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Fig. 5 PolII transcriptional speed modulates the amount of incomplete splicing of Htt. a Chromatin immunoprecipitation of minigene associated RNA PolII.
The schematic shows the position of the qPCR assays on the minigene (to scale). Data are mean ± s.e.m.; n≥ 5 independent ChIPs/CAG-length, Student’s
t-test. Regression ﬁts were calculated from the individual data points. CAG-length: *p < 0.05. Data represents % recovered PolII normalized to input
transcript levels (see also methods section). b 5′ UTR levels in the (CAG)7 or (CAG)100 expressing minigene lines. Data are mean ± s.e.m.; n≥ 22
independent experiments, Student’s t-test. c–f 5,6-dichlorobenzimidazole 1-β-D-ribofuranoside (DRB) treatment. Data are mean ± s.e.m.; n≥ 4 independent
treatments/CAG-length/concentration, two-way ANOVA with Tukey post hoc test. Regression ﬁts were calculated from the individual data points.
Treatment: *p < 0.05, ***p < 0.001. Treatment x CAG-length #p < 0.05, ##p < 0.01, ###p < 0.001. c–e Data are shown as the ratio to the respective DMSO
treated sample. c 5′ UTR levels indicate either less transcription of the minigenes at higher DRB concentrations, cytotoxicity at higher DRB concentrations,
or a combination of both. d Normalized spliced exon 1-exon 2 levels were signiﬁcantly higher at high DRB concentrations in the (CAG)100 versus the
(CAG)7 lines. e The reduction of intron 1 containing sequences was very similar for both CAG repeat lengths. f Treatment with DRB resulted in a signiﬁcant
reduction of minigene intron 1 containing sequences for both CAG repeat lengths
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amount of mis-spliced Atxn335. Intriguingly, this might
have generated a similar ‘road block’ for transcription of Atxn3
as to that which we have accomplished by tethering the dCas9
enzyme to the Htt minigenes (Fig. 6). This ‘road block’
could lead to premature termination of transcription, or
attenuation of elongation rates, and thus kinetically allow the
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Fig. 7 Schematic depicting mechanisms inﬂuencing incomplete splicing of HTT in HD. In the normal situation (left panel), U1 snRNP protects cryptic polyA
sites from being utilized and deﬁnes the 5′ splice site at the exon 1/intron 1 junction. Transcription by PolII is fast and thus HTT is properly spliced and the
full-length mRNA is produced. In HD (right panel), there is an increased amount of SRSF6 binding to the elongated CAG repeat, which could sequester
U1 snRNP resulting in interference with 5′ spliceosome formation and cryptic polyA site de-protection. In addition, transcription throughout the 5′ end of
the gene is slower, kinetically allowing a higher probability of cryptic polyA site usage. Together, these mechanisms lead to the generation of HTTexon1
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Fig. 6 CRISPR/dCas9 induced obstacles of transcription increase the amount of incomplete splicing of Htt. a Schematic showing the binding sites of the
four different guide RNAs (gRNA I-IV). b–e Transcript analysis of minigene sequences. Left panels show expression levels standardized to housekeeping
genes. Data in the right panels are additionally normalized to 5′ UTR levels for the respective gRNA treatment. Individual data points and the mean ± s.e.m.
are shown. n= 4 independent experiments/CAG-length/gRNA, two-way ANOVA with Tukey post hoc test. gRNA for given CAG-length: *p < 0.05, **p <
0.01, ***p < 0.001. gRNA x CAG-length #p < 0.05, ##p < 0.01, ###p < 0.001. b gRNA I treatment reduced the level of minigene transcripts (5′ UTR). gRNA
II c and gRNA III d treatment had no signiﬁcant effect on transcript levels. e gRNA IV treatment resulted in a signiﬁcant increase of intron 1 containing
sequences
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We have shown that the transcription of minigenes that con-
tain an elongated CAG repeat is slower than that of minigenes
containing short repeats (Fig. 5a, b). The current hypothesis of
transcriptional termination, is that PolII pauses due to a combi-
nation of chromatin marks, DNA:RNA hybrid structures (R-
loops) and termination factors24. Pausing of PolII is also linked to
splicing. PolII transiently pauses at the 3′ end of introns37, at
terminal exons38 and there is a polyA site dependent control step
that induces premature transcription termination28. In the mouse
Htt minigenes, the intronic region that includes a GT/GA
microsatellite and a predicted hairpin structure was necessary to
induce incomplete splicing (Fig. 1). This microsatellite does not
exist in the human HTT gene, where the cryptic polyA site that is
utilized is 7327 bp into intron 1. However, there is a CA/TA
microsatellite (8443 bp from the exon 1/intron 1 junction) fol-
lowed by a predicted hairpin (at 9057 bp). Both elements,
microsatellites and stem-loops, have been shown to be sufﬁcient
to terminate transcription in some eukaryotic genes39,40. CA
expansions that are not bound to the protective hnRNP L41 lead
to cleavage of pre-mRNA upstream of the expansion42. Taken
together, these elements in intron 1 of the HTT gene could
attenuate/terminate transcription elongation and open up a
kinetic window for utilization of the cryptic polyA sites.
Negative elongation factor (NELF) and DSIF (5,6-dichloro-1-
β-D-ribofuranosylbenzimidazole (DRB) sensitivity inducing fac-
tor) are both needed for PolII pausing at promoter proximal
sites43. DSIF comprises the mammalian homologs of SPT4 and
SPT544. DRB (Fig. 5) inhibits the elongation factor P‐TEFb
through inhibition of cyclin-dependent kinase 9 (CDK9), which
in turn causes an increase in the DSIF mediated pausing of
PolII45,46. Such promoter proximal pausing at the HTT locus
could be reﬂected by the increased amount of PolII observed at 5′
UTR sequences (Fig. 5a). RNA PolII holoenzyme needs to acquire
the speciﬁc elongation factor SPT4/SUPT4H1 (SPT4 homolog,
DSIF elongation factor subunit) to be able to transcribe efﬁciently
through CAG repeats47. Increased interaction of DSIF, in parti-
cular the SPT4 subunit, with PolII by DRB treatment could
improve transcription through the repeat, and consequently,
throughout the gene. This would decrease the likelihood of
cryptic polyA site usage and decrease the amount of incomplete
splicing (Fig. 5d–f). Furthermore, DRB blocks the phosphoryla-
tion of DISF (SPT5 subunit) through inhibition of CDK9, which
is a prerequisite for PolII to pass the polyA checkpoint of tran-
scription termination28. Therefore, DRB treatment could lead to
PolII not passing the polyA checkpoint at the cryptic polyA site in
intron 1 and thus effectively blocking the maturation of
HTTexon1, shifting the steady state levels towards properly
spliced Htt (Fig. 5d–f).
In summary, using our model system of incomplete splicing of
Htt, we uncovered multiple regulatory mechanisms that inﬂuence
the amount of HTTexon1 production (Fig. 7). We showed that a
precise spatial relation of the CAG repeat to the 5′ splice site and
speciﬁc intronic sequences was necessary for the formation of
HTTexon1. Furthermore, modulation of the levels of SRSF6, a
general splicing factor, regulated the levels of HTTexon1. Finally,
we demonstrated that PolII transcription elongation and termi-
nation determine if the cryptic polyA sites in intron 1 are utilized
and HTTexon1 is produced. These ﬁndings unravel some of the
fundamental requirements for incomplete splicing of HTT lead-
ing to a more detailed view of the processes that drive HD
pathogenesis. It has been shown that stabilizing the 5′ splice site
spliceosome assembly with a small molecule at the exon 7-intron
7 junction of the SMN2 gene (survival of motor neuron 2)
resulted in a marked increase of incorporation of exon 7 into the
mature mRNA48,49. Our system could provide the basis of a high-
throughput screen for small molecules that modulate incomplete
splicing and thereby help to develop future therapeutics for HD.
Methods
Generation and maintenance of stable cell lines. We used the Flp-In™ system
(ThermoFisher) to generate all cell lines. This system permits the generation of
stable cell lines within an isogenic background that only differs due to the inte-
grated sequence. We used the Flp-In™−293 human embryonic kidney cell line as
the parent line (R750-07, ThermoFisher). All cell culture supplies were purchased
from ThermoFisher. The integration procedure of the cell lines was performed
according to the manufacturer’s instructions. The stably integrated cell lines were
selected with 100 µg/ml hygromycin B (10687010). We expanded at least 3 single
cell clones through four passages to a T75 stage, which was designated passage 0.
Every cell line was repeat sized (as described in14) at this stage to ensure that lines
had the desired CAG repeats and to exclude those that had changed through CAG
repeat instability during the integration procedure. Growth medium was DMEM
(11960085), 10% (v/v) FBS (16000044), 2 mM L-glutamine (25030024), 100 U Pen/
Strep (15140122), 100 µg/ml hygromycin B (10687010). Cells were passaged when
they reached approximately 90–95% conﬂuence, usually every 3 days. All cell lines
were routinely checked for mycoplasma contamination.
Generation of plasmids used in this study. All Htt sequences are based on NCBI
accession number 15194 (murine Htt), genome build NC_000071.6 bases 34760737
to 34913521. We used the Herculase (Agilent) PCR system for cloning according to
the manufacturer’s protocol. In cases where CAG repeats longer than 40 CAGs
were ampliﬁed, 5% dimethyl sulfoxide was added to the PCR reactions.
The following plasmids were generated by cloning PCR products from wild type
genomic DNA (CBA × C57BL/6) into pCR2.1-TOPO-TA vectors (Life
Technologies). Primers are given in brackets (see also Supplementary Table 1):
about 1 kb of murine Htt promoter (pHtt1_f, pHtt1_r)= pHtt1; 5′ UTR, exon1
and the ﬁrst 98 bp of Htt intron 1 (pHtt2_f, pHtt2_r)= pHtt2; the following 819 bp
of Htt intron 1 after the end of pHtt2 (pHtt3_f, pHtt3_r)= pHtt3; the following
3054 bp of Htt intron 1 after the end of pHtt2 (pHtt3_f, pHtt30_r)= pHtt30; the
last 338 bp of Htt intron1, exon2, FLAG-tag (pHtt6_f, pHtt6_r)= pHtt6; about
650 bp of the 3′UTR of exon 67 of Htt (pHtt7_f2, pHtt7_r2) including the
endogenous polyA site= pHtt7. All plasmid sequences were validated by
sequencing: pHtt1: from the NotI site C426G and G764T; pHtt2: no change; pHtt3:
from the KpnI site T300A and T461C; pHtt30: from the KpnI site T300A, T461C,
T2697G, T2843C; pHtt6: no change; pHtt7: no change. Some nucleotide changes
like T300A, T461C from the KpnI site were found in independently ampliﬁed and
cloned plasmids. They therefore most likely represent deviations from the NCBI
deposited mouse genome due to the different mouse strains and not PCR
introduced mutations.
To generate the backbones for the integration plasmids with different intron
lengths, the CMV-promoter was cut from pcDNA5/FRT (Life Technologies) with
SpeI/EcoRV, the plasmid was re-ligated and sequenced to give pHtt8. pHtt1 was
subcloned with NotI/PmeI into pHtt8 to give pHtt9. pHtt2 was subcloned with
BamHI/PmeI into pHtt9 to give pHtt10. pHtt6 was subcloned with MfeI/BamHI
into pHtt7 to give pHtt11. pHtt3 was subcloned with KpnI/MluI into pHtt11 to
give pHtt12. pHtt12 was subcloned with KpnI/PmeI into pHtt10 to give pHtt15
(short intron backbone, contains (CAG)7 repeat). A PCR from pHtt11 (pHtt32_f,
pHtt7_r2) was cloned into pCR2.1-TOPO-TA to give pHtt32. pHtt30 was
subcloned KpnI/SbfI into pHtt32 to give pHtt14. pHtt14 was subcloned KpnI/PmeI
into pHtt10 to give pHtt17 (long intron backbone, contains (CAG)7 repeat).
pHtt30 was cut with SacI/SbfI, re-ligated and sequenced to give pHtt13. pHtt13 was
subcloned KpnI/PmeI into pHtt10 to give pHtt16 (medium intron backbone,
contains (CAG)7 repeat).
To generate different CAG repeat lengths, PCR products consisting of 5′ UTR,
exon1 and the ﬁrst 98 bp of Htt intron 1 (pHtt2_f, pHtt2_r) from genomic DNA of
different knock-in lines were cloned into pCR2.1-TOPO-TA. Template: HdhQ50
= pHtt18; HdhQ100= pHtt19; HdhQ150= pHtt20. CAG repeat lengths in the
range from 20 to 45 were obtained by random priming in the CAG repeat from an
HdhQ50 genomic DNA template in the ﬁrst PCR (two separate PCRs: pHtt2f/
CTG7 and CAG7/pHtt2r). The PCR products were puriﬁed and used as templates
in a second PCR (pHtt2f/pHtt2r). Products of different sizes were cloned into
pCR2.1-TOPO-TA. All plasmid sequences were validated by sequencing and
showed no changes. Each BamHI/KpnI fragment was subcloned into the
backbones of pHtt15 (short), pHtt16 (medium) and pHtt17 (long) to give the ﬁnal
integration plasmids. pHtt21= (CAG)50 short intron; pHtt22= (CAG)100 short
intron; pHtt23= (CAG)150 short intron; pHtt24= (CAG)50 medium intron;
pHtt25= (CAG)100 medium intron; pHtt26= (CAG)150 medium intron; pHtt27
= (CAG)50 long intron; pHtt28= (CAG)100 long intron; pHtt29= (CAG)150 long
intron; pHtt37= (CAG)32 long intron; pHtt38= (CAG)23 long intron; pHtt39=
(CAG)41 long intron; pHtt40= (CAG)37 long intron; pHtt41= (CAG)23 medium
intron; pHtt42= (CAG)41 medium intron.
To generate plasmids that only expressed exon 1 sequences, the parent vectors
with different CAG repeat lengths were cut with NheI/PmeI and re-ligated. pHtt33
= (CAG)7; pHtt34= (CAG)50; pHtt35= (CAG)100; pHtt36= (CAG)150.
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To generate integration plasmids to study the position dependency of the CAG
repeat, PCR products from a (CAG)23 and a (CAG)100 containing plasmid were
cloned into pCR2.1-TOPO-TA and sequenced. In addition to the CAG repeat, the
plasmids contained 19 bp adjacent upstream and 18 bp adjacent downstream
sequences. Primers for BamHI integrated CAG repeats were BamHIF/BamHIR;
KpnI: KpnIF/KpnIR; HincII: HincIIF/HincIIR; NdeI: NdeIF/NdeIR. All plasmid
sequences were validated by sequencing and showed no changes.
Human SDHA (NCBI gene ID: 6389) and SPP1 (NCBI gene ID: 6696)
minigenes were cloned from genomic DNA extracted from the HEK293 cell line.
Both PCR products (SDHA: SDHAf/SDHAr; SPP1: SPP1f/SPP1r) were ﬁrst cloned
into pCR2.1-TOPO-TA and the 5′ and 3′ ends of the minigenes were conﬁrmed by
sequencing. The CAG repeats were introduced and subsequently, the constructs
were subcloned KpnI/BamHI into pCR5/FRT. The minigenes were under the
control of a CMV promoter and a bGH terminator. Furthermore, in all constructs
an ATG start codon was introduced 5′ of the ﬁrst cloned exon.
Mouse (NCBI gene ID: 67996) and human (NCBI gene ID: 6431) SRSF6
overexpression plasmids were cloned including a 5′ Kozak sequence. Mouse or
human cDNA, respectively, was used as the PCR template. Primers were: human
SRSF6: hmSF6f-K/hSF6r; mouse Srsf6: hmSF6f-K/mSF6r. The PCR products were
cloned BamHI/NotI into pcDNA3. Constructs were under the control of a CMV
promoter.
pAC84-pCR8-dCas9 was a gift from Rudolf Jaenisch (Addgene plasmid #
48218)50. MLM3636 was a gift from Keith Joung (Addgene plasmid # 43860). The
coding sequence for dCas9 was transferred to the Gateway™ pT-Rex™-DEST30
Vector (ThermoFisher) according to the manufacturer’s instructions. MLM3636
was digested with BsmBI and the four gRNA were introduced. To this end,
complementary oligonucleotides (see Supplementary Table 1) were annealed and
ligated into the cut MLM3636. The expression was driven by the human U6
promoter. gRNA plasmids were sequenced and contained no mutations.
Overexpression plasmids for SRSF1, SRSF2 and SRSF3 were obtained from
Addgene. SRSF1 was a gift from Honglin Chen (Addgene plasmid # 99021)51.
SRSF2 was a gift from Kathleen Scotto (Addgene plasmid # 44721)52. SRSF3 was a
gift from David Bartel (Addgene plasmid # 46736)53.
Transfection, siRNA, CRISPR/dCas9 and drug treatments. 2.5 × 105 cells were
seeded in a 6-well plate. Experiments were initiated on the following day, and cells
were analyzed 48 h later for transfections, or 6 h later for drug treatments. All
DNA/RNA transfections were performed with the jetPRIME® system (Polyplus-
transfection) according to the manufacturer’s instructions. For plasmid transfec-
tions, 1 µg of plasmid was transfected. For siRNA transfections, 30 nM ﬁnal con-
centration siRNAs were transfected. For CRISPR/dCas9 experiments, 1 µg dCas9
plasmid and 1 µg of each gRNA plasmid were transfected. Drugs were solubilized
in 100% dimethyl sulfoxide (DMSO) as stock solutions, aliquoted and kept at −20 °
C. Stocks solutions were: 5,6-dichlorobenzimidazole 1-β-D-ribofuranoside (DRB)
10 mM; actinomycin D (ActD) 1 mM; (S)-(+)-camptothecin (CAM) 10mM; 1-
hydroxypyridine-2-thione zinc salt (zinc) 50 mM. Working solutions were pre-
pared on the day of the experiment and pre-diluted with 100% DMSO to a 200-fold
higher concentration than the desired ﬁnal concentration. Finally, 10 µl of the drug
solutions, or 100% DMSO (0.5% ﬁnal concentration of DMSO) were added to a 6
well plate (2 ml medium), mixed and incubated for 6 h at 37 °C.
Quantitative real-time PCR and 3′RACE. RNA was extracted using QIAZOL
together with RNeasy Mini kits (Qiagen) according to the manufacturer’s
instructions. 2–4 µg total RNA was reverse transcribed with MMLV (Invitrogen,
Moloney murine leukemia virus) using the UAPdT primer and according to the
manufacturer’s instructions. For 3′RACE analysis, the RT reaction mix was
digested with 1U of RNase H (Invitrogen) for 1 h at 37 °C. The cDNA was sub-
sequently diluted 1:10 in water and 2 μl were used as template. For qPCR analysis,
the RT reactions were diluted with water (1:10) and analyzed on a CFX96 (Bio-
Rad). For details about primers and probes see Supplementary Table 2. We used
Taqman RT quantitative PCR (qPCR) with multiplexed assays. Multiplexing was as
follows (ﬂuorophore in brackets): ACTB (FAM)+ splice ex1/ex2 −19f (TexasRed)
+ 5′ UTR (Cy5.5); ATP5B (FAM+HTT ex66/67 (Cy5.5); SDHA (FAM)+ intron
1 (TexasRed)+ spliced ex1/ex2 −34f (Cy5.5). All assays were tested for reprodu-
cibility of the results in the multiplexed versus single runs. All other assays were
performed as single runs. For Fig. 1d–f, the geometric mean of the two spliced ex1/
ex2 (−19f and −34f) assays was used to generate the graphs. For all other ﬁgures
only the spliced ex1/ex2 −19f was used. Evaluation of the data was performed
using the ΔΔCt evaluation method54. The geometric mean of the expression levels
of the following housekeeping genes was used to standardize the samples:
Figs. 1d–f, 3a, b, 3d, e, 4b, c, 5b, 6b–e, Supplementary Fig. 3, Supplementary Fig. 4,
Supplementary Fig. 6A-6D: ATP5B, ACTB and SDHA, Fig. 6c–f and Supplemen-
tary Fig. 6C-6E: ATP5B and ACTB. Primers used for 3′RACE and qPCR are listed
in Supplementary Table 1.
Prediction of polyA sites and terminators and sequencing. To predict polyA
sites in intron 1 of Htt, we used the SoftBerry polyAH algorithm (http://linux1.
softberry.com/all.htm). Transcription terminator like regions were predicted using
ARNold55. Sequencing was performed on a ABI3730xl DNA analyzer using the Big
Dye Terminator 3.1 mix (ABI) according to the manufacturer’s protocol.
3B5H10 immunoprecipitation, western blotting and antibodies. HTT immu-
noprecipitation (IP) was carried out with 3B5H10 (Sigma-Aldrich) coupled mag-
netic beads (M-270 Epoxy, ThermoFisher). The coupling procedure was as
described in13. Cells were lysed in ice-cold NET buffer (50 mM HEPES pH 7.4, 100
mM NaCl, 0.5% (w/v) Triton X-100, 1 mM EDTA) supplemented with cOmplete™
protease inhibitors (Sigma-Aldrich). 25 µg of total lysate was collected as inputs.
500 µg total protein extract was mixed with an equal volume of dilution buffer (50
mM HEPES pH 7.4, 220 mM NaCl, 1% (w/v) Triton X-100, 20 mM EDTA, 0.2%
(w/v) SDS, 0.4% (w/v) Na-deoxycholate, 4 mM DTT, 1:500 PMSF supplemented
with cOmplete™ protease inhibitors (Sigma-Aldrich)). 10 µl 3B5H10 coupled
magnetic beads were added and the mix was incubated for 4 h at 4 °C with slight
agitation. IPs were washed 4 times with each 0.4 ml of wash buffer (50 mM HEPES
pH 7.4, 160 mM NaCl, 1% (w/v) Triton X-100, 10 mM EDTA, 0.1% (w/v) SDS,
0.2% (w/v) Na-deoxycholate, 2 mM DTT, 1:1000 PMSF supplemented with
cOmplete™ protease inhibitors (Sigma-Aldrich)). Bound proteins were eluted by
heating the washed beads with HU buffer (200 mM Tris-Cl pH 6.8, 8 M urea, 5%
(w/v) SDS, 1 mM EDTA pH 8.0, 215 mM β-mercaptoethanol) for 10 min at 65 °C.
Inputs were also mixed with an equal amount of HU buffer.
Samples from the immunoprecipitation were loaded onto a 16% poly-
acrylamide gel. Samples for analysis of SR protein expression were loaded onto a
12% poly-acrylamide gel. Separated proteins were transferred onto a nitrocellulose
membrane (Bio-Rad) and blocked for 1 h with blocking buffer (5% (w/v) skimmed
milk powder in TBS-T (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 0.1% (w/v) Tween
20)). All blots were incubated with primary antibodies over night at 4 °C in TBS-T.
Wash buffer was TBS-T. Secondary antibodies (1:5000 in TBS-T for 45 min at
room temperature) were purchased from LI-COR and western blots were
visualized on an Odyssey Sa (LI-COR) and analyzed with the Image Studio Lite Ver
3.1 (LI-COR). Antibody dilutions were as follows: anti-FLAG (2368P, Cell
Signaling) 1:100; anti-HTT (MW8) (CHDI-90000942-1, CHDI Foundation) 1:250;
anti-HTT (S830) (in-house) 1:500; anti-SRSF6 (ab140623, Abcam) 1:1000; anti-
SRSF1 (sc-33652, Santa Cruz Biotechnology) 1:500; anti-p-SRSF2 (sc-53518, Santa
Cruz Biotechnology) 1:500; anti-SRSF3 (sc-398541, Santa Cruz Biotechnology)
1:500; anti-SDHA (ab14715, Abcam) 1:10000.
Chromatin immunoprecipitation. 1∙106 cells were seeded in a 150 mm petri dish
with 40 ml of growth medium and 80–90% conﬂuence was reached after 3 days of
incubation. DNA and bound proteins were cross-linked with 1% formaldehyde
(SigmaAldrich) for 5 min at 30 °C on an orbital shaker (150 rpm). The crosslinking
reaction was quenched by addition of 125 mM glycine for 5 mins at RT on an
orbital shaker (150 rpm). The cells were rinsed with DPBS (14190250, Thermo-
Fisher), scraped off, transferred into a test tube and pelleted (RT, 2 min, 500 g). The
pellet was lysed with 200 µl lysis buffer (50 mM Tris-Cl pH 8.0, 1% (w/v) SDS, 10
mM EDTA pH 8.0, supplemented with cOmplete™ protease inhibitors (Sigma-
Aldrich)) and incubated for 5 min on ice. The cross-linked DNA was sheared by
sonication in a bioruptor sonicator (UCD-200 TO, Diagenode) with settings 30 s
on and 60 s off, high intensity, 20 cycles. The resulting fragment length was
checked on 2.5% agarose gel and was about 300 bp. The sonicated lysate was
centrifuged for 7 min at 4 °C. The DNA concentration was measured against the
SDS lysis buffer on a nanodrop 1000 (ThermoFisher). Immunoprecipitation (IP)
was carried out with 100 µg of chromatin. 2 µg of each antibody, anti-RNA poly-
merase II CTD repeat YSPTSPS (phospho S2) (ab5095, Abcam) and rabbit IgG
(2729, Cell Signaling) were used for IP. The samples were mixed with 4 times the
volume of ChIP dilution buffer (20 mM Tris-Cl pH 8.0, 0.1% (w/v) SDS, 1% (w/v)
Trition X-100, 150 mM NaCl, 2 mM EDTA pH 8.0, supplemented with cOmplete™
protease inhibitors (Sigma-Aldrich)) and incubated overnight at 4 °C on a rotating
wheel. Prior to purifying the antibody bound complexes, 5% input was taken from
all samples for data normalization. Pre-washed (SDS lysis buffer) dyna protein G
beads were then added to IPs and incubated for 3 h at 4 °C on turning wheel. The
IP reactions were washed for 5 min at RT with 0.5 ml of each wash buffer: 2 times
low salt (50 mM HEPES pH 7.4, 150 mM NaCl, 0.1% (w/v) sodium deoxycholate,
1% (w/v) Triton X-100, 1 mM EDTA pH 8.0), high salt (50 mM HEPES pH 7.4,
500 mM NaCl, 0.1% (w/v) sodium deoxycholate, 1% (w/v) Triton X-100, 1 mM
EDTA pH 8.0), LiCl (10 mM Tris-Cl pH 8.0, 250 mM LiCl, 0.5% (w/v) sodium
deoxycholate, 0.5% (w/v) NP-40, 1 mM EDTA pH 8.0)) and 2 times TE (10 mM
Tris-Cl pH 8.0, 1 mM EDTA pH 8.0). IPs were eluted twice with SDS elution buffer
(50 mM Tris-Cl pH 8.0, 1% (w/v) SDS, 10 mM EDTA) for 20 min at 70 °C. The
combined elutions were incubated overnight at 70 °C. The next day, 1.5 µg of
RNase A (ThermoFisher) per IP was added and incubated at 37 °C for 30 min. 40
µg glycogen (ThermoFisher) and 60 µg proteinase K (ThermoFisher) were added
and the reactions were incubated at 37 °C for 2 h. Puriﬁed DNA was extracted
using the Qiagen PCR puriﬁcation kit (28104) and resuspended in 10 mM Tris pH
8.0 for further analysis.
Analysis of transcriptomic data bioinformatics analysis. Count data for the
zQ175 mouse datasets were obtained from the HDinHD website (www.hdinhd.org,
downloaded on 17/01/2018)56. For the human post-mortem cortex data, sra ﬁles
(GSE79666) were downloaded from GEO (www.ncbi.nlm.nih.gov/geo), mapped to
the GRCh38 release 90 human transcriptome (www.ensembl.org) with STAR
v2.5.3a57 and quantiﬁed with Salmon v0.8.258. All datasets were analyzed for batch
effects, gender corrected (limma v3.34.859) and outliers removed. Dysregulation
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was computed using tximport v1.6.060 and DESeq2 v1.18.161. Spliceosome com-
ponents were downloaded from KEGG (www.genome.jp/kegg; mmu03040;
hsa03040) and the transcript dysregulation data was mapped onto the common
genes. Networks were generated with Cytoscape v3.6.062.
Statistical analysis. All data were screened for outliers using a Grubbs’ test
(GraphPad). All data were analyzed with IBM SPSS using a two-tailed homo-
scedastic Student’s t-test or a two-way ANOVA with either Tukey or Bonferroni
post hoc test as speciﬁed in the ﬁgure legends. P-values < 0.05 were considered to
be statistically signiﬁcant. To determine the type of regression ﬁt for data in
Figs. 2, 5 and in Supplementary Fig. 3, we calculated regression ﬁt statistics and
chose the most signiﬁcant ﬁt. Regression ﬁts were calculated from the individual
data points. Regression statistics can be found in Supplementary Table 3.
Data availability
Count data for the zQ175 mouse datasets were obtained from the HDinHD website
(www.hdinhd.org, downloaded on 17/01/2018). The human post-mortem cortex data
were downloaded from GEO (www.ncbi.nlm.nih.gov/geo, GSE79666). The authors
declare that the data supporting the ﬁndings of this study are available within the paper
and its supplementary information ﬁles. Scripts for the bioinformatics analysis are freely
available upon request from the corresponding authors.
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